pharma · Prostate Cancer · Hot Flush
Astellas Pharma
Astellas Pharma GmbH
Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Ga
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 22
- Drugs
- 52
- Patents
- 25
A study to find a suitable dose of ASP5834 in adults with solid tumors
Phase 1 · other · Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification
A study to find a suitable dose of ASP5834 in adults with solid tumors for Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification is a Phase 1 program (other) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code 5834-CL-1001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Astellas Pharma GmbH
- Phase
- Phase 1
- Modality
- other
- Indication
- Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification
- Status
- active
- Trials
- 1